Silver Spike II (SPKB) to Receive Shares from Terminated Eleusis Deal
by Nicholas Alan Clayton on 2022-09-26 at 7:04am

Silver Spike Acquisition Corp. II (NASDAQ:SPKB) announced in an 8-K filing this morning that it would be receiving shares as compensation for the termination of its merger agreement with biopharmaceutical firm Eleusis.

The parties terminated the merger on June 9, but the breakup fee has been subject to continued negotiation. The SPAC is now to receive an amount of shares equal to 3% of Eleusis’ total equity at its next capital raise, liquidity event or sale of the company. Should this occur after Silver Spike II has consummated a different business combination or liquidated, then these shares will be placed in escrow with a third-party payment agent.

For now, Silver Spike II says it will continue to seek a new business combination and has until March 15, 2023 under its original deadline to do so. The team closed its first deal in 2021 with WM Holding, an ecommerce platform connecting consumers with local cannabis products.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

by Nicholas Alan Clayton on 2024-04-16 at 7:58am

At the SPAC of Dawn Ever since Digital World announced its combination with Trump Media (NASDAQ:DJT) back in October 2021, it was clear that SPACworld and the Trump show were set to be intertwined for quite some time. And, although not every headline has a bearing on the wider SPAC world, Trump Media’s post-close rise...

by Nicholas Alan Clayton on 2024-04-15 at 3:47pm

AltC (NYSE:ALCC) has reportedly been taking the pitch deck for its combination with nuclear fission firm Oklo on the road in recent weeks, which has generated the rare result of a SPAC trading significantly above its trust value still well before completing its deal. The SPAC has an estimated $10.59 per share in its trust...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved